Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details Narrative)

v3.20.1
Subsequent Events (Details Narrative) - Subsequent Event [Member]
1 Months Ended
Mar. 31, 2020
shares
Number of warrants will receive in agreement 100,000
License agreement description In March 2020 we signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of our WoundShield technology. Under the terms of the agreement, NanoVibronix will receive 100,000 warrants of Sanuwave stock, a $250,000 milestone payment based on FDA approval, and 10% royalty on Sanuwave's gross revenues from sales or rentals of WoundShield. In return, Sanuwave has received the worldwide, exclusive rights to the company's WoundShield product and technology.
Royalty percentage 10.00%